Recurrence of meningiomas

Yamasaki, Fumiyuki; Yoshioka, Hiroyuki; Hama, Seiji; Sakamoto, Kazuhiko; Arita, Kazunori; Kurisu, Kaoru

doi:10.1002/1097-0142(20000901)89:5<1102::aid-cncr20>3.0.co;2-l

Cited by 162 publications

(84 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of progressionfree survival of patients with Grade 2 me ningiomas is approximately 50% at 5 years. 6,26 Multiple surgical procedures are usually required to control tumor recurrences. Repeated surgeries are associated with in creased morbidity, which can seriously affect a patient's quality of life.…”

Section: Natural History Of Grade 2 Meningiomamentioning

confidence: 99%

Grade 2 meningioma and radiosurgery

Aboukaïs¹,

Zaïri²,

Lejeune³

et al. 2015

JNS

View full text Add to dashboard Cite

OBJECT World Health Organization Grade 2 meningiomas are aggressive tumors associated with a high recurrence rate leading to repeated surgical procedures, which can seriously worsen a patient's neurological status. Although radiosurgery is an increasingly popular technique, its role in the management of Grade 2 meningiomas has yet to be defined. In this study the authors aimed to evaluate radiosurgery in achieving control of proven tumor progression occurring after resection of Grade 2 meningioma. METHODS This retrospective study included consecutive patients who, between 2000 and 2012, had undergone radiosurgery for radiologically proven progression of a previously surgically treated Grade 2 meningioma. RESULTS Twenty-seven patients were eligible for analysis. There were 9 men and 18 women with a mean age of 59 years. The mean radiation dose was 15.2 Gy (range 12–21 Gy), and the mean target volume was 5.4 cm3 (range 0.194–14.2 cm3). Thirty-four radiosurgical procedures were performed in the 27 patients. The mean progression-free survival after radiosurgery was 32.4 months among those with progression in a target irradiated volume and 26.4 months among those with progression in any intracranial meninges. With a mean follow-up of 56.4 months (range 12–108 months), the 12-, 24-, and 36-month actuarial local control rates for all patients were 75%, 52%, and 40%, respectively, and the regional control rates were 75%, 48%, and 33%. A single case of transient hemiparesis completely resolved without sequelae. CONCLUSIONS Radiosurgery appears to be a safe and effective treatment for the local control of delayed progression after resection of a Grade 2 meningioma. Higher radiation doses similar to those applied for malignant tumors should be recommended when possible.

show abstract

Section: Natural History Of Grade 2 Meningiomamentioning

confidence: 99%

Grade 2 meningioma and radiosurgery

Aboukaïs¹,

Zaïri²,

Lejeune³

et al. 2015

JNS

View full text Add to dashboard Cite

show abstract

“…Yamasaki et al 32 have described their experience following Simpson Grade 1 resections in 54 patients with convexity meningiomas. Six patients (11.1%) in this series had evidence of recurrent tumor on follow-up, with vascular endothelial growth factor exRisk profile associated with convexity meningioma resection in the modern neurosurgical era pression and a high MIB-1 labeling index-both found to be predictors of recurrence.…”

mentioning

confidence: 99%

Risk profile associated with convexity meningioma resection in the modern neurosurgical era

Sanai¹,

Sughrue²,

Shangari³

et al. 2010

JNS

View full text Add to dashboard Cite

Object. Although meningiomas are commonly found along the supratentorial convexity, the risk profile associated with this subset of lesions in the modern neurosurgical era is unknown.Methods. The authors retrospectively reviewed the clinical course of patients with supratentorial convexity meningiomas treated during the past 10 years. All patients had undergone MR imaging within 72 hours after surgery and at least 1 year of clinical follow-up. Patients with multiple meningiomas, hemangiopericytomas, malignant meningiomas, or tumor-prone syndromes were excluded from analysis.Results. Between 1997 and 2007, 141 consecutive patients (median age 48 years, range 18-95 years) underwent resection of a supratentorial convexity meningioma. The most common signs or symptoms at presentation were headache (48%), seizures (34%), and weakness (21%). The mean tumor volume was 146.3 cm 3 (range 1-512 cm 3). There were no intraoperative complications or deaths. Medical or neurosurgical morbidity was noted in the postoperative course of 14 patients, equating to a 10% overall complication rate. Postoperative surgical complications included hematoma requiring evacuation, CSF leakage, and operative site infection. Medical complications included pulmonary embolus and deep vein thrombosis requiring treatment. A Simpson Grade 0 or 1 resection was achieved in 122 patients (87%). One hundred six tumors (75%) were WHO Grade I, whereas 35 (25%) were WHO Grade II. The median clinical follow-up was 2.9 years (range 1-10 years), and the median radiographic follow-up was 3.7 years (range 1-10 years). Six patients (4%) had radiographic evidence of tumor recurrence, with 3 (2%) undergoing repeat resection.Conclusions. With the conservative recommendations for surgery for asymptomatic meningiomas and the advent of radiosurgery during the past 10 years, microsurgically treated convexity meningiomas are now typically large in size. Nevertheless, the patient's clinical course following microsurgical removal of these lesions is expected to be uncomplicated. The authors' findings provide a defined risk profile associated with the resection of supratentorial convexity meningiomas in the modern neurosurgical era.

show abstract

“…[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] Among them, Ki-67 (MIB-1), a tumor proliferation antigen, appears to be the best and is widely accepted as a biomarker for meningioma prognosis. As a general rule, the Ki-67 proliferation index correlates well with WHO tumor grade for meningioma.…”

Section: -7mentioning

confidence: 99%

The Oncofetal Protein IMP3: A Novel Molecular Marker to Predict Aggressive Meningioma

Hao¹,

Smith²,

Chu³

et al. 2011

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

N Context.-One of the major clinical challenges is to predict recurrence of meningioma. Recently, we have found that IMP3, an oncofetal RNA-binding protein, is a biomarker to predict aggressive tumors.Objective.-To investigate whether IMP3 can be used as a new biomarker to predict the recurrence and overall survival of patients with meningiomas.Design.-One hundred seven patients with primary meningiomas were investigated for expression of IMP3 by immunohistochemistry and whether expression of this molecule correlated with tumor recurrence and overall survival.Results.-Tumor recurrence was found in 13 of 107 patients with primary meningioma. Seven of 107 patients (6.5%) with primary meningiomas expressed IMP3. Kaplan-Meier plots and log-rank tests showed that patients with IMP3-positive tumors had a much higher recurrence rate (P = .004) and a poorer overall survival (P , .001) than did patients with IMP3-negative tumors. The 5-year recurrence-free and overall survival rates were 0% and 36% in IMP3-positive patients versus 89% and 94% in IMP3-negative patients, respectively. Multivariable analysis of IMP3 status (positive versus negative) in primary tumors showed a hazard ratio of 17.89 for recurrence (P = .01), which was much higher than hazard ratios associated with all other known risk factors including higher tumor grades and Ki-67 labeling index.Conclusions.-IMP3 is a potential independent prognostic biomarker that can be used at the time of initial diagnosis of meningioma to identify patients who have a high risk of developing a recurrence.

show abstract

Recurrence of meningiomas

Cited by 162 publications

References 51 publications

Grade 2 meningioma and radiosurgery

Grade 2 meningioma and radiosurgery

Risk profile associated with convexity meningioma resection in the modern neurosurgical era

The Oncofetal Protein IMP3: A Novel Molecular Marker to Predict Aggressive Meningioma

Contact Info

Product

Resources

About